ICUCW — SeaStar Medical Holding Corporation

Summary of SeaStar Medical Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: Reported net revenue from Quellimmune sales was approximately $183,000 for Q3 2025, a significant increase from $68,000 in Q3 2024.
• Gross Profit Margin: Achieved a gross profit margin of 92%, reflecting the first full quarter of cost of goods sold matched against sales.
• Operating Expenses: Decreased to $3.7 million from $4.5 million in the prior year, primarily due to reduced consulting and personnel costs.
• Net Loss: Reported a net loss of approximately $3.5 million or $0.13 per share, an improvement from a net loss of $4.5 million or $1.10 per share in Q3 2024.
• Cash Position: Cash reserves increased to $13.8 million from $1.8 million at year-end 2024, bolstered by raising $12.4 million through equity offerings and warrant exercises.

2. Strategic Updates and Business Highlights

• Customer Base Expansion: Added three top-ranked children's medical centers, increasing the total to 10 active commercial pediatric hospitals.
• Clinical Data: Presented survival results from the SAVE surveillance registry, showing 76% survival at 60 days and 71% at 90 days for 21 pediatric patients treated with Quell immune therapy.
• Trial Progress: Completed an interim analysis of the neutralized AKI pivotal trial, confirming safety and recommending an increase in enrollment from 200 to 339 patients to ensure adequate statistical power.
• New Clinical Trials: Launched a new trial for treating cardiorenal syndrome (CRS) in patients with chronic systolic heart failure, aiming to enroll 20 patients.

3. Forward Guidance and Outlook

• Revenue Projections: Anticipating full-year revenue for 2025 to exceed $1 million, with early Q4 sales already surpassing Q3 figures.
• Growth Strategy: Focus on expanding the number of pediatric hospital sites and improving the adoption process for Quellimmune therapy to create a more predictable revenue stream.

4. Challenges and Points of Concern

• Enrollment Challenges: The requirement for a data safety monitoring board has slowed site activation and patient enrollment for clinical trials, although efforts are being made to expedite this process.
• Variable Sales: Revenue remains somewhat volatile and variable from quarter to quarter, which poses a risk to achieving consistent financial performance.
• Regulatory Risks: The need for FDA approval for expanded use and the potential impact of regulatory changes on trial timelines and market entry.

5. Notable Q&A Insights

• Enrollment Update: As of the call, 146 patients have been enrolled in the neutralized AKI trial, with 17 sites activated and plans to activate 8 more to reach the new target of 339 patients by December 2026.
• New Trial Details: The CRS trial is in early stages, with expectations to enroll 20 patients over the next year, focusing on a unique patient population not suitable for mechanical support.
• Revenue Confirmation: Management confirmed they are on track to achieve over $1 million in revenue for 2025, addressing concerns about revenue variability.

This summary encapsulates the key points from SeaStar Medical's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.